Compare ASTS & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTS | INSM |
|---|---|---|
| Founded | 2019 | 1988 |
| Country | United States | United States |
| Employees | 578 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0B | 23.0B |
| IPO Year | N/A | 2000 |
| Metric | ASTS | INSM |
|---|---|---|
| Price | $70.75 | $107.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 24 |
| Target Price | $72.10 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 22.7M | 4.5M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $167.10 | $182.31 |
| Revenue Next Year | $391.80 | $65.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.50 | $90.39 |
| 52 Week High | $133.86 | $212.75 |
| Indicator | ASTS | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 40.16 | 53.99 |
| Support Level | $67.68 | $98.90 |
| Resistance Level | $87.47 | $166.81 |
| Average True Range (ATR) | 8.11 | 5.12 |
| MACD | -3.18 | 2.33 |
| Stochastic Oscillator | 19.10 | 98.73 |
AST SpaceMobile Inc is currently designing, developing and manufacturing the constellation of BlueBird (BB) satellites and has begun launching its planned space-based Cellular Broadband network distributed through a constellation of low Earth orbit (LEO) satellites. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.